Trial Profile
A Trial Comparing Efficacy and Safety of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST™ : START 1)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec/insulin aspart (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BOOST; BOOST-START-1
- Sponsors Novo Nordisk
- 11 Sep 2013 Planned number of patients changed from 526 to 752 as reported by European Clinical Trials Database record.
- 11 Sep 2013 Planned number of patients changed from 526 to 752 as reported by European Clinical Trials Database record.
- 07 Feb 2011 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India record.